SOURCE: Market Pulse

December 01, 2005 08:30 ET

Market Pulse Breaking News Alert for Thursday, December 1, 2005: LFTC -- Lifestream Technologies Signs Agreement With GenExel for New Three-in-One Unit!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Market Pulse.

ATLANTA, GA -- (MARKET WIRE) -- December 1, 2005 --Market Pulse News Alert for this AM, Stocks to Watch are: Lifestream Technologies, Inc. (OTC BB: LFTC), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Google Inc. (NASDAQ: GOOG), and JDS Uniphase Corp. (NASDAQ: JDSU).

Investors need to be watching Lifestream Technologies, Inc. (OTC BB: LFTC) this AM! Lifestream develops, markets and sells a line of smart card-enabled healthcare diagnostic devices. Lifestream has developed and currently markets a line of cholesterol monitors that provide test results in three minutes for at-home use by health conscious consumers and at-risk medical patients. Lifestream just had excellent news out in a press release before today's opening bell announcing that it has entered into an agreement with GenExel-Sein, Inc., for the production of the new Lifestream three-in-one blood pressure monitor! This could be great news for investors!

Lifestream Technologies, Inc. (OTC BB: LFTC), a leading supplier of cholesterol monitors, announced today that it has entered into an agreement with GenExel-Sein, Inc., for the production of the new Lifestream Three In One Blood Pressure monitor.

"We are pleased that, after over 6 months of review and discussions with numerous blood pressure manufacturers, GenExel met our stringent quality standards and had the clarity of vision for this market opportunity," stated Christopher Maus, Lifestream's CEO. "This new technology will complement our product line and expand our present market opportunities in an area not yet commercialized."

The new Lifestream "Three-in-One" Blood Pressure monitor will measure blood pressure, cholesterol and HDL, all in less than three minutes. Consumer awareness for cholesterol testing can be significantly expanded through this merger. Between 5 to 7 million blood pressure monitors are sold each year in the U. S. or 14 million worldwide.

"The health conscious consumer, who uses or will use a blood pressure monitor, now has a real clear choice," continued Maus. "This dual use device supplies more meaningful information about a consumer's cardiac health. The combined unit is also more cost effective and will play an essential role for individuals who are managing both blood pressure and cholesterol. There is an estimated 73% overlap of individuals with elevated blood pressure and high cholesterol. About 20 million people are on both blood pressure and cholesterol lowering medications."

"GenExel is pleased to be partnering with Lifestream on this very innovative product," said Dr. Douglas Stafford, Executive Vice President of GenExel. "Lifestream understands the market as much as GenExel does. This collaboration is perfect given that GenExel is also bringing an innovative Blood Pressure/Glucose monitor to the market. This product is a natural evolution for the hypertensive market. Together, Lifestream and GenExel have an opportunity to meet the goals of both companies and give health conscious consumers more quality choices."

About GenExel-Sein, Inc.

GenExel is a rapidly growing medical products company with headquarters in South Korea. Its business units provide innovative products for home medical diagnosis and engage in the discovery and development of pharmaceutical products with an emphasis on central system disorders (such as Alzheimer's disease and Parkinson's disease). The company has operating subsidiaries in South Korea, China, Germany, the United Kingdom, and the United States. It is traded publicly on the KOSDAQ under the symbol GENEXEL. For more information, visit GenExel-Sein online at or Contact: GenExel-Sein, Inc., 111 Seocho-Gu, YangJae-1 Dong, Namkyung Bldg 3rd Floor 137-891, Seoul, South Korea, for more information on the company.

About Lifestream Technologies

The Company developed and currently markets a cholesterol monitor to consumers and healthcare professionals that provide total cholesterol test results in three minutes. The Company's product aids the health conscious consumer in monitoring their risk of heart disease. By regularly testing cholesterol at home, individuals can monitor the benefits of their diet, exercise and/or drug therapy programs. Monitoring these benefits can support the physician and the individual's efforts to improve compliance. Lifestream's products also integrate a smart card reader further supporting compliance by storing test results on an individual's personal health card for future retrieval, trend analysis and assessment.

Lifestream's monitors are affordable, hand-held devices that provide users with accurate results in less than three minutes. The product line has been designed to accommodate The Data Concern™ Personal Health Card® allowing multiple users the ability to store their personal results. Lifestream's products are now available in pharmacy and retail outlets nationwide. To find retailers that carry Lifestream's products, go to "Store Locator" on or contact Customer Care at 888-954-LIFE. For Company information, visit

Stocks in the news and acting well as of late include: BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Google Inc. (NASDAQ: GOOG), and JDS Uniphase Corp. (NASDAQ: JDSU).

Information contained herein is the opinion of ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP was compensated by a third party shareholder with three million free trading shares of common stock of Lifestream Technologies, Inc. ("Lifestream"). MP was also compensated an additional three million restricted shares of common stock directly from Lifestream. The restricted shares that MP received directly from Lifestream were subsequently registered by Lifestream with the Securities and Exchange Commission and may now be resold by MP without restriction. To date, MP has sold three million shares of stock in Lifestream for proceeds totaling ninety five thousand and three hundred dollars. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives free trading shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services. and Market Pulse Breaking News Alert are owned by Market Pulse LLC.

Contact Information